Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Study of Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma

NCT07649304 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07649304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07649304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Study of Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 9, 2026
Completion date
April 30, 2028
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related diffuse large b-cell lymphoma, diffuse large b-cell lymphoma, not otherwise specified, high grade b-cell lymphoma with myc and bcl2 rearrangements, high grade b-cell lymphoma, not otherwise specified, lugano classification stage ii adult non-hodgkin lymphoma ajcc v8, lugano classification stage iii adult non-hodgkin lymphoma ajcc v8, lugano classification stage iv adult non-hodgkin lymphoma ajcc v8, plasmablastic lymphoma, primary effusion lymphoma